Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Biodesix (BDSX) Operating Expenses (2019 - 2025)

Historic Operating Expenses for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to $28.8 million.

  • Biodesix's Operating Expenses rose 776.68% to $28.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $112.7 million, marking a year-over-year increase of 1241.21%. This contributed to the annual value of $105.8 million for FY2024, which is 1702.11% up from last year.
  • Biodesix's Operating Expenses amounted to $28.8 million in Q3 2025, which was up 776.68% from $29.7 million recorded in Q2 2025.
  • In the past 5 years, Biodesix's Operating Expenses registered a high of $34.4 million during Q1 2021, and its lowest value of $18.9 million during Q4 2021.
  • Moreover, its 5-year median value for Operating Expenses was $23.5 million (2022), whereas its average is $24.5 million.
  • In the last 5 years, Biodesix's Operating Expenses skyrocketed by 15483.8% in 2021 and then plummeted by 3901.42% in 2022.
  • Biodesix's Operating Expenses (Quarter) stood at $18.9 million in 2021, then rose by 24.3% to $23.5 million in 2022, then fell by 8.34% to $21.5 million in 2023, then increased by 25.72% to $27.1 million in 2024, then rose by 6.43% to $28.8 million in 2025.
  • Its Operating Expenses was $28.8 million in Q3 2025, compared to $29.7 million in Q2 2025 and $27.1 million in Q1 2025.